Published in final edited form as:

Bioorg Med Chem. 2008 May 15; 16(10): 5653–5664. doi:10.1016/j.bmc.2008.03.066.

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 6. Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine

Mark P. Wentland^{*,a}, Xufeng Sun^a, Dana J. Cohen^b, and Jean M. Bidlack^b

^aDepartment of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY 12180, USA

^bDepartment of Pharmacology and Physiology, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA

Abstract

A series of 7,8- and 8,9-fused pyrimidinone, aminopyridine and pyridone derivatives of 8-carboxamidocyclazocine (8-CAC) have been prepared and evaluated in opioid receptor binding assays. Targets were designed to corroborate a pharmacophore hypothesis regarding the bioactive conformation of the carboxamide of 8-CAC. In addition to the results from this study strongly supporting this pharmacophore hypothesis, a number of novel compounds with high affinity to opioid receptors have been identified.

1. Introduction

We reported in 2001¹ our observation that the prototypic phenolic OH group of certain opioids can be replaced by a carboxamide group (CONH₂) and retain high affinity binding to opioid receptors. For example, binding affinities for 8-carboxamidocyclazocine (8-CAC, **1**) were K_i (nM) = 0.31, 5.2 and 0.06 for μ , δ and κ , respectively, while for cyclazocine (**2**),² the K_i values were within 2-fold. For other 2,6-methano-3-benzazocines (a.k.a. benzomorphans)¹ as well as quadracyclic morphinans [e.g., cyclorphan (**3**)],³ the ratio of binding affinities [K_i (CONH₂)/ K_i (OH)] for μ and κ receptors was also near unity in most cases. However, for pentacyclic 4,5 α -epoxymorphinans [e.g., morphine (**4**) and naltrexone (**5**)], that ratio was much higher indicating the CONH₂ derivative displayed much lower affinity than its corresponding phenolic OH counterpart. For example, the K_i (CONH₂)/ K_i (OH) ratio for μ was 35 and 7 for the morphine and naltrexone pairs, respectively.⁴ For the CONH₂ partner **6** of naltrexone (**5**), we observed that the most stable conformation of the unbound ligand was that represented by **6** which is stabilized via intramolecular H-bonding of the furan O to the carboxamido NH.⁵ Since this compound had much lower binding affinity than would be predicted from SAR studies, we reasoned that the putative bioactive conformation was **7** rather than **6** and that **6** must pay an energy penalty to adopt the putative bioactive conformation **7** resulting in lower affinity. For 2,6-methano-3-benzazocines and morphinans [e.g., 8-CAC (**1**)] the putative carboxamide bioactive conformation (as shown in **1**) is among many a number of stable conformations and is one that can easily be attained since there is no barrier created by H-bonding to a neighboring ether bridge.

*Corresponding author. Tel.: +1 518 276 2234; fax: +1 518 276 4887; e-mail: wentmp@rpi.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

To test this conformational hypothesis, we designed, prepared and evaluated the 4-hydroxy-3-caboxamido-naltrexone analogue **8** in which the newly introduced 4-OH was found to stabilize the carboxamide in the putative bioactive conformation shown in **8** and not the alternative conformation **9**.⁵ Compound **8** displayed extraordinarily high affinity for μ receptors ($K_i = 0.052$ nM) and high affinity for δ and κ receptors. When compared to **6**, compound **8** had binding affinities 14-, 212- and 50-fold higher against μ , δ and κ , respectively. We also showed that the benefit of the 4-OH was to stabilize the putative bioactive conformation and not through direct contact with the receptor.

We now report additional studies where the overall goal was to confirm or refute this conformational hypothesis. Objectives to meet this goal were a) the design and preparation of analogues where we constrained the carboxamido (or surrogate) group of 8-CAC in the putative bioactive conformation **1** through covalent bonds rather than through non-covalent H-bonds as discussed above and b) evaluation of new targets in opioid receptor binding assays. Previously reported carboxamide SAR studies revealed that the H-bond donating and accepting properties of the CONH_2 group were important for recognition by opioid receptors and that highly basic groups at the 8-position were not tolerated.^{1,6} Keeping these SAR trends in mind, we designed the 8,9- and 7,8-fused 8-CAC derivatives **10** and **12**, respectively, as mimics of the putative carboxamide bioactive conformation as shown is **1**. We also made derivatives **11** and **13** as controls (i.e., forcing the carboxamide into a conformation believed not to be the bioactive one). Further validation of our pharmacophore hypothesis would be evident if **10** and **12** had higher affinity for opioid receptors than **11** and **13**, respectively.

2. Results

2.1. Chemistry

The first step in the syntheses of racemic target compounds **10-13** involved the nitration of cyclazocine (**2**) under standard conditions to provide a mixture of nitro derivatives **18** and **19** easily separated using silica gel flash chromatography (Scheme 1). Compounds **18** and **19** were treated with $\text{PhN}(\text{SO}_2\text{CF}_3)_2$ and triethylamine in CH_2Cl_2 to provide triflate esters **20** and **21**, respectively, in high yields. Compounds **20** and **21** were then converted to nitriles **22** and **23**, respectively, by the use of $\text{Zn}(\text{CN})_2$ and $\text{Pd}(\text{PPh}_3)_4$ in DMF under microwave radiation. Partial hydrolysis of nitriles **22** and **23**, using KOH and *t*-BuOH gave carboxamides **24** and **25**, respectively. Subsequent reduction of the nitro groups of **24** and **25** using standard conditions provided the corresponding amines **26** and **27** which upon treatment with formic acid under microwave radiation provided the target derivatives **10** and **11**, respectively.

Target compound **12** was prepared as shown in Scheme 2. Carboxamide derivative **26** (from Scheme 1) was dehydrated using POCl₃ and pyridine under microwave radiation to provide nitrile intermediate **28** which was then treated with HC(OMe)₃ to provide **29**. Compound **29** was treated with ammonia to give the target pyrimidine derivative **12**. To assess the effect of *N*-substitution of target **12**, we made the (4'-phenyl)-phenethyl and benzyl derivatives **14** and **15** by treating intermediate **29** with (4'-phenyl)-phenethylamine and benzylamine, respectively.

Target **13** having the same aminopyrimidine ring fusion as **12** but at the 8,9-positions was made using a slight modification of the methodology just described. As shown in Scheme 3 intermediate **23** (from Scheme 1) was reduced using hydrogen and 10% Pd/C in methanol to provide intermediate **30** which was then treated with trimethyl orthoformate to provide imide **31**. Exposure of **31** to ammonia and methanol under microwave radiation provided target **13**.

As shown in Scheme 4, we also made the (4'-phenyl)-phenethyl and benzyl derivatives **16** and **17**, respectively, by treating intermediate **32** with (4'-phenyl)-phenethylamine and benzylamine, respectively. Using conditions similar to those previously reported,⁷ compound **32** was made by exposing **27** (from Scheme 1) to POCl₃ and DMF under microwave radiation.

Lastly, novel fused 8,9-pyridinone analogue **37** was prepared as shown in Scheme 5. Activated ester intermediate **33**⁸ was treated with methoxylamine hydrochloride in pyridine to afford *N*-methoxycarboxamide **34**. Using a general method previously described for making pyridinones,⁹ intermediate **34** was lithiated at the sterically less encumbered 9-position and at nitrogen using sec-butyllithium in the presence of TMEDA at -20 °C. The resulting dianion was quenched with methyl iodide to provide the 9-methylated derivative **35**. Lithiation of **35** with excess sec-butyllithium at -78 °C followed by a DMF quench gave the *N*-methoxypyridinone derivative **36**. Titanium trichloride reduction of **36** provided target **37**.

2.2. Biology

Target compounds were evaluated for their affinity and selectivity for μ , δ and κ opioid receptors stably expressed in Chinese hamster ovary (CHO) cell membranes. The details of these assays are found in the experimental section and data are summarized in Table 1. Opioid binding affinity data for 8-CAC (**1**) and the two *N*-alkylated 8-CAC analogues **38** and **39** are also included. All compounds in Table 1 are racemic. Against the δ receptor, binding affinity for all new targets in Table 1 was low (K_i = 35 to >10,000 nM) relative to their affinities for μ and κ opioid receptors. Therefore, we focused our analysis of the data on the μ and κ receptors. For target compounds **10-13**, binding affinities for the μ opioid receptor ranged from very high (e.g., K_i = 0.55 nM for **12**) to very low (e.g., K_i = 890 nM for **13**). Affinity for the κ receptor was good for targets **10** and **12** with K_i values of 12 nM and 1.0 nM, respectively, while for compounds **11** and **13**, affinity was very low (K_i values of 160 nM and 560 nM, respectively). With the exception of target **14**, binding affinities of the *N*-substituted aminopyrimidine analogues **14-17** were relatively weak for μ and κ receptors (K_i = 28-88 nM and 48-240 nM, respectively). For **14**, however, affinities for μ and κ were good with K_i values of 6.9 nM and 8.6 nM, respectively. The pyridinone target **37** had high affinity μ and κ receptors (K_i values of 5.5 nM and 0.74 nM, respectively). Lastly, the binding affinities of a number of synthetic intermediates were assessed. For μ and κ receptors, 7-nitro-containing compounds **18** (K_i = 32 nM and 3.2 nM, respectively) and **24** (K_i = 20 nM and 34 nM, respectively) had reasonably good affinity, while the corresponding 9-nitro-containing compounds **19** and **25** had very poor affinities (K_i values in the range of 110-3800 nM). The 7-amino variant **26** of 8-CAC had very high affinity for μ and κ with K_i = 0.55 nM and 0.70 nM, respectively, while affinities of its regioisomer **27** were much lower (K_i = 88 nM and 32 nM, respectively).

Three compounds, **12**, **26** and **37**, that displayed high affinity for μ and κ receptors were characterized in a [^{35}S]GTP γ S assay to assess functional activity. These data are summarized in Table 2. Due to the relatively poor binding affinity to δ receptors, these compounds were not evaluated for functional activity at δ . Target compound **12** was found to be an antagonist at both μ and κ receptors and **26** to be an antagonist at μ and moderate agonist at κ . Compound **37** displayed weak mixed agonist/antagonist properties at μ and for κ , it was an agonist. Functional activity for **38**, another highly potent in the binding assays, has been previously reported.^{12,13} It is an antagonist at μ and an agonist at δ and κ receptors.

3. Discussion

For the two 8,9- and 7,8-fused-pyrimidinone targets **10** and **11**, respectively, our pharmacophore hypothesis predicts the former to have relatively high affinity for μ and κ receptors and the latter predicted to have low affinity. Against the κ receptor we do, in fact, observe a significant difference in the binding affinities of **10** and **11**. As predicted, target **10** has reasonably high affinity ($K_i = 12$ nM) and compound **11** has low affinity ($K_i = 160$ nM). Against the μ receptor, however, we do not observe the same divergence. While target **11** did, as predicted, exhibit low affinity for μ ($K_i = 270$ nM) target **10** did so as well ($K_i = 170$ nM). It may well be that the carboxamide group embedded in **10** is in the proper bioactive conformation and its poor binding affinity is due to the substantial structural change at position-9 relative to 8-CAC (9-H). In other words, unlike the κ receptor, μ poorly accommodates substitution at position-9 of 2,6-methano-3-benzaocines. There are several data points in this study that support such an argument. As shown in Table 1, the 9-nitro variants **19** and **25** of cyclazocine and 8-CAC, respectively, have much lower affinity for μ and κ receptors than their 7-nitro counterparts **18** and **24**. Also, the 9-amino variant **27** of 8-CAC displays considerable lower affinity for the receptors than its 7-amino counterpart **26**. There are data, however, that contradict this argument. Opioids with a fused 8,9-fused aminothiazole ring (2,6-methano-3-benzaocine numbering) or aminooxazole ring are reported to have high affinity for μ receptors.¹⁰ In another study, cyclazocine derivatives with a 8,9-fused imidazole or triazole ring are also characterized by having high affinity for the μ receptor.¹¹ Besides one based on an invalid pharmacophore hypothesis, the only other explanation that comes to mind regarding the poor activity of **10** at the μ receptor is that the electron withdrawing imine part of the pyrimidinone ring reduces the H-bond accepting ability of the carboxamide oxygen. To test this premise, we prepared the pyridinone derivative **37** where the imine N of **10** is replaced by a non-electron withdrawing CH. Physical data that support such a premise is seen in the downfield chemical shift [δ 8.05 (s, 1H)] of the CH on the pyrimidinone ring of **10** relative to that [δ 7.15 (d, 1H, $J = 7.0$ Hz)] of the corresponding CH of **37**. Compound **37** has high affinity for the μ receptor ($K_i = 5.5$ nM) and is 31-fold more potent than the corresponding pyrimidinone **10**. Pyridinone **37** also has very high affinity for the κ receptor ($K_i = 0.74$ nM) and has 16-fold higher affinity than **10**. These results fit nicely with the premise that an electron withdrawing group at position-9 is detrimental for binding. They also support of the overall hypothesis that the carboxamide structure embedded in **37** is in the bioactive conformation. We attempted to make the analogue of **37** having a 7,8-fusion, however, we were unsuccessful using a similar method to that used to make **37**.

For the 7,8- and 8,9-fused-aminopyrimidine targets **12** and **13**, respectively, our pharmacophore hypothesis predicts **12** to have relatively high affinity for μ and κ receptors and **13** predicted to have low affinity. This is precisely what we observe. Compound **12** has K_i values of 0.55 nM and 1.0 nM against μ and κ , respectively and **13** has K_i values of 890 nM and 560 nM against μ and κ , respectively. For an aminopyrimidine surrogate of a carboxamide, these data indicate our pharmacophore hypothesis is reinforced.

In earlier SAR studies, we reported that *N*-substitution of the carboxamide of 8-CAC (**1**), with groups such as methyl, OH, NH₂ or phenyl greatly reduced binding affinity, however, when the substituent was a (4'-phenyl)-phenethyl group (**38**) binding affinity for μ and κ receptors was very high (K_i values of 0.30 nM and 1.8 nM, respectively).^{1,12,13} We hypothesized that the *N*-(4'-phenyl)-phenethyl appendage occupies a previously unexplored hydrophobic pocket in opioid receptors.^{12,13} We also made the corresponding *N*-benzyl 8-CAC analogue **39** which had much lower affinity for μ and κ receptors (K_i values of 27 nM and 36 nM, respectively).¹² To study the additivity of SAR between the 8-CAC and 7,8-fused-aminopyrimidine platforms, we prepared and evaluated analogues **14** and **15** of aminopyrimidine target **12** by appending (4'-phenyl)-phenethyl and benzyl groups to the exocyclic nitrogens which correspond to the carboxamide N of 8-CAC. Data from Table 1 reveal that introduction of a (4'-phenyl)-phenethyl group in the 7,8-fused aminopyrimidine core (compare **12** and **14**) results in a 13- and 48-fold decrease in binding affinity against μ and κ , respectively. These data contrast the 8-CAC core μ results (compare **1** and **38**) where *N*-substitution with a (4'-phenyl)-phenethyl group results in comparable binding affinity; against κ there is a similar decrease (30-fold) in binding affinity. With a *N*-benzyl substituent (compare **12** and **15**), there is a 80- and 240-fold decrease in binding affinity against μ and κ , respectively. This decrease in binding affinity parallels the decrease observed upon introduction of an *N*-benzyl group into 8-CAC (compare **1** and **39**) where an 87- and 600-fold decrease in binding affinity against μ and κ , respectively, is observed. We also made and tested the *N*-(4'-phenyl)-phenethyl and *N*-benzyl analogues in the much less active 8,9-fused-aminopyrimidine platform **13**. In contrast to the 7,8-fused system **12**, the addition of the hydrophobic appendages to **13** enhances binding affinity for μ and κ 32- and 4-fold, respectively, for the (4'-phenyl)-phenethyl derivative **16** and 10- and 12-fold, respectively, for the benzyl analogue **17**. Absolute binding affinities, however, are relatively weak.

38: R = CH₂CH₂(4-C₆H₄C₆H₅)

39: R = CH₂C₆H₅

Examination of binding data for synthetic intermediates **18**, **19** and **24-27**, revealed that nitro substitution on the 7- or 9-positions of the aromatic ring was detrimental to binding for both cyclazocine (compare **2** to **18** and **19**) and 8-CAC (compare **1** to **24** and **25**). It is noteworthy that when nitro is at position-7 in cyclazocine and 8-CAC (i.e., **18** and **24**, respectively), binding affinities are much higher than the corresponding 9-nitro derivatives **19** and **25**. The observation that the 7-amino variant **26** of 8-CAC had very high affinity for μ and κ (K_i = 0.55 nM and 0.70 nM, respectively) suggests the amino group stabilizes the carboxamide in the putative bioactive conformation as depicted in **26a**. While the proton NMR of **26** in CDCl₃ suggests the presence of an intramolecular H-bond between the CONH₂ and adjacent NH₂, we can not tell whether the most stable form is **26a** or **26b**. Abraham aromatic H-bond structural constants for ArCONH₂ are 0.49 (H-bond acidity) and 0.53 (H-bond basicity) and for ArNH₂, they are 0.26 (H-bond acidity) and 0.27 (H-bond basicity).¹⁴ These data would lead one to conclude that **26a** and **26b** would have similar stabilities, however, the ArCONH₂ and ArNH₂ groups are considered in isolation in this analysis. In **26**, the groups are, of course,

conjugated which may well tip the scale on favor of **26a**; this would be highly consistent with our view on stabilization of the carboxamide group in the bioactive conformation by H-bonding with an adjacent OH group (e.g., **8**). The relatively poor activity of the 9-amino regioisomer **27** ($K_i = 88$ nM and 32 nM, respectively) may be due to a) poor tolerance of the receptor to 9-substitution and/or b) the 9-amino group stabilizing the carboxamide in a conformation other than the bioactive one.

All three compounds, **12**, **26** and **37**, that were characterized in the [35 S]GTP γ S assay, were found to be antagonists at the μ receptor, although **37** was a mixed agonist/antagonist. For the three compounds at the κ receptor, however, a divergence in functional activity was observed. Whereas **26** and **37** were agonists at κ , compound **12** was an antagonist.

4. Conclusions

Opioid receptor binding affinity data for novel target compounds **10-14** and **37** were used in this SAR study to substantiate and strengthen our pharmacophore hypothesis that the carboxamide bioactive conformation of 8-CAC and related opioids is that depicted by **1** versus rotomers where the carboxamide is rotated about the C-C bond to the aryl ring. This conclusion is based on the observed (and predicted) high affinity binding of a) compound **12** for μ and κ relative to **13** and b) compound **10** for κ relative to **11**. The poor affinity of **10** for μ was not as predicted and seemingly contradicts our underlying hypothesis. However, by the design and evaluation of **37**, a highly active close analogue of **10**, we now believe the poor μ affinity of **10** is due to a weakening of the H-bond accepting ability of its carboxamide due to presence of the electron withdrawing imine moiety embedded in the heterocyclic ring. Not only does the observed high μ affinity of **37** help explain the poor activity of **10**, it also strengthens our underlying pharmacophore hypothesis since this compound rigidifies the carboxamide group in the putative bioactive conformation.

From our data, it is apparent that target **12** and 8-CAC (**1**) share a common pharmacophore. Therefore, we expected that the effect of substituting the carboxamide N of 8-CAC with, for example, a (4'-phenyl)-phenethyl group (i.e., **38**) would be very similar to that same substitution on the exocyclic N of **12** (e.g., **14**). While the impact on κ affinity is similar across both platforms (i.e., 30-fold decrease for the **1** $\rightarrow$ **38** conversion and 9-fold decrease for **12** $\rightarrow$ **14**), there is a significant divergence on μ affinity (i.e., **1** and **38** have same affinity and a 13-fold decrease is seen for the **12** $\rightarrow$ **14** conversion). This divergence may be a consequence of a conformational change of the carboxamide group of **38** (relative to 8-CAC) to facilitate interaction of the *N*-(4'-phenyl)-phenethyl group with its putative complimentary hydrophobic binding site. For **14**, the aminopyrimidine surrogate of the carboxamide can't undergo conformational change due to its rigidified nature. This may weaken the stability of the putative hydrophobic interaction between the (4'-phenyl)-phenethyl group and receptor. In summary, there appears to be no benefit in binding affinity when a (4'-phenyl)-phenethyl or benzyl group

is appended to the exocyclic nitrogen of **12**. While binding affinity is increased when the groups are attached to **14**, absolute potency is relatively weak.

Assuming the intramolecular H-bond between the neighboring amino and carboxamide groups of **26** and **27** is due to H-bond donation by the amine and accepting by the carboxamide oxygen, the observation that **26** has much higher affinity for μ and κ receptors than **27** adds further credence to our pharmacophore hypothesis.

In summary, the value of the SAR data generated in this study is not only the strengthening of our underlying pharmacophore hypothesis, but also in the identification of a number of novel opioids having high affinity to μ and κ receptors. These novel compounds (e.g., **12** and **26**) have drug-like structures suitable for additional studies to aid in the selection of clinical candidates. Additional SAR studies in this area are ongoing in our laboratories and will be the subject of future communications.

5. Experimental

5.1. Chemistry

Proton NMR spectra and in certain cases ^{13}C NMR were obtained on a Varian Unity-300 or 500 NMR spectrometer with tetramethylsilane as an internal reference for samples dissolved in CDCl_3 . Samples dissolved in CD_3OD and $\text{DMSO}-d_6$ were referenced to the solvent. Proton NMR multiplicity data are denoted by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublets), and br (broad). Coupling constants are in hertz. Direct insertion probe chemical ionization mass spectral data were obtained on a Shimadzu GC-17A GC-MS mass spectrometer. Direct infusion electrospray ionization (in positively charged ion mode) mass spectral data were obtained on an Agilent 1100 series LC/MSD system (Germany). Melting points were determined on a Meltemp capillary melting point apparatus and were uncorrected. Infrared spectral data were obtained on a Perkin-Elmer Paragon 1000 FT-IR spectrophotometer. Reactions performed under microwave radiation were done on a Personal Chemistry Creator system (20W). The assigned structure of all test compounds and intermediates were consistent with the spectral data. Carbon, hydrogen, and nitrogen elemental analyses for all novel targets were performed by Quantitative Technologies Inc., Whitehouse, NJ, and were within $\pm 0.4\%$ of theoretical values except as noted; the presence of water or other solvents was confirmed by proton NMR. Reactions were generally performed in an argon or nitrogen atmosphere. Commercially purchased chemicals were used without purification unless otherwise noted. Silica gel (Bodman Industries, ICN SiliTech 2-63 D 60A, 230-400 Mesh) was used for all flash chromatography. Where indicated, an Isco CombiFlash Companion was used for purification of reaction products. Toluene and Et_2O were distilled from sodium metal. THF was distilled from sodium/benzophenone ketyl. Pyridine was distilled from KOH. Methylene chloride was distilled from CaH_2 . DMF and DMSO were distilled from CaH_2 under reduced pressure. Methanol was dried over $3\text{\AA}$ molecular sieves prior to use.

Cis-($\pm$)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-7-nitro-2,6-methano-3-benzazocine-8-ol (18**) and cis-($\pm$)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-9-nitro-2,6-methano-3-benzazocine-8-ol (**19**)—A**

solution of 69% nitric acid (0.20 g) in 2.0 mL glacial acetic acid was added to a solution of cyclazocine² (**1**; 0.542 g, 2.0 mmol) in 3.0 mL glacial acetic acid at 25 °C. After stirring at 25 °C for 3 h, TLC indicated the presence of starting material and an additional 0.10 gm of 69% nitric acid was added. After stirring 2 h at 25 °C, TLC indicated all starting material was consumed and the reaction mixture was poured into a mixture of ice and excess concentrated ammonium hydroxide. The mixture was treated with ethyl acetate and the organic phase was washed with brine, dried over Na_2SO_4 , filtered, and concentrated to give a crude solid product which was purified by gradient silica gel flash chromatography ($\text{CH}_2\text{Cl}_2:\text{CH}_3\text{OH}$; 20:1 $\rightarrow$

10:1) to give **18** (0.26 g, 40%) as a brownish solid and **19** (0.35 g, 54%) as a brownish foam: Recrystallization from MeOH/CH₂Cl₂ gave yellow crystals having mp 145 °C and mp 175 °C, respectively.

For **18**: ¹H NMR (500 MHz, CDCl₃) δ 6.98 (d, 1H, *J* = 8.3 Hz), 6.83 (d, 1H, *J* = 8.5 Hz), 3.10 (m, 1H), 2.84 (d, 1H, *J* = 18.8 Hz), 2.81-2.57 (m, 2H), 2.46 (m, 1H), 2.32 (m, 1H), 2.03 (m, 3H), 1.86-1.66 (m, 1H), 1.31 (s, 3H), 1.25 (m, 1H), 0.87 (m, 4H), 0.51 (m, 2H), 0.11 (m, 2H); MS (ESI) *m/z* 317 (M+H)⁺; Anal. Calcd. for C₁₈H₂₄N₂O₃·0.75 H₂O: C 65.53, H 7.79, N 8.49. Found: C 65.27, H 7.41, N 8.23.

For **19**: ¹H NMR (500 MHz, CDCl₃) δ 10.36 (s, 1H), 7.80 (s, 1H), 7.03 (s, 1H), 3.16 (m, 1H), 2.95 (d, 1H, *J* = 18.8 Hz), 2.79-2.56 (m, 2H), 2.48 (m, 1H), 2.32 (m, 1H), 1.96 (m, 3H), 1.39 (s, 3H), 1.36 (m, 1H), 0.85 (m, 4H), 0.52 (m, 2H), 0.11 (m, 2H); MS (ESI) *m/z* 317 (M+H)⁺; Anal. Calcd. for C₁₈H₂₄N₂O₃·0.5 H₂O: C 66.44, H 7.74, N 8.61. Found: C 66.03, H 7.33, N 8.48.

Trifluoromethanesulfonic acid, cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-7-nitro-2,6-methano-3-benzazocine-8-yl ester (20)—

Triethylamine (0.22 g, 2.22 mmol) was added to a solution of **18** (0.47 g, 1.48 mmol) dissolved in 20 mL of CH₂Cl₂. PhN(SO₂CF₃)₂ (0.58 g, 1.63 mmol) was then added and the resulting mixture stirred at 25 °C for 4 h. The solvent was removed on a rotary evaporator and the resulting mixture was purified by gradient silica gel flash chromatography (CH₂Cl₂:CH₃OH; 80:1 → 40:1) to give **20** (0.59 g, 88%) as a yellow foam. ¹H NMR (500 MHz, CDCl₃) δ 7.30 (d, 1H, *J* = 8.5 Hz), 7.24 (d, 1H, *J* = 8.6 Hz), 3.56 (m, 1H), 3.17 (m, 1H), 3.05 (m, 2H), 2.81 (m, 1H), 2.66 (m, 1H), 2.29-2.04 (m, 2H), 1.90 (m, 1H), 1.34 (m, 4H), 0.87 (m, 4H), 0.69 (m, 2H), 0.28 (m, 2H).

Trifluoromethanesulfonic acid, cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-9-nitro-2,6-methano-3-benzazocine-8-yl ester (21)—

Using a procedure similar to that used to prepare **20**, compound **19** was converted to **21** (93%) as a yellow foam. ¹H NMR (500 MHz, CDCl₃) δ 7.94 (s, 1H), 7.27 (s, 1H), 3.60 (m, 1H), 3.22-2.94 (m, 3H), 2.84 (m, 1H), 2.68 (m, 1H), 2.30 (m, 1H), 2.11 (m, 2H), 1.41 (s, 3H), 1.38 (m, 1H), 0.84 (m, 4H), 0.69 (m, 2H), 0.29 (m, 2H).

Cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-7-nitro-2,6-methano-3-benzazocine-8-carbonitrile (22)—To a tube containing **20** (0.27 g, .061 mmol) was added under a N₂ blanket, Zn(CN)₂ (0.14 g, 1.22 mmol) and Pd(PPh₃)₄ (0.07 g, 0.061 mmol). DMF (degassed with N₂, 3.0 mL) was then added via a cannula under N₂. The resulting mixture was irradiated with microwaves at 150 °C for 15 min. The resulting mixture was partitioned between water and EtOAc. The organic phase was washed with water (X2) and brine, and then dried over Na₂SO₄, filtered, and concentrated to give a crude product which was purified by silica gel flash chromatography (CH₂Cl₂:CH₃OH:NH₄OH;80:1:0.1) to give **22** (0.14 g, 70%) as an off-white foam. ¹H NMR (500 MHz, CDCl₃) δ 7.52 (d, 1H, *J* = 8.1 Hz), 7.35 (d, 1H, *J* = 8.1 Hz), 3.20 (m, 1H), 3.04 (d, 1H, *J* = 19.1 Hz), 2.86 (m, 1H), 2.68 (m, 2H), 2.47 (m, 1H), 2.34 (m, 1H), 2.10-1.74 (m, 3H), 1.34 (m, 4H), 0.89 (m, 1H), 0.84 (d, 3H, *J* = 7.1 Hz), 0.54 (m, 2H), 0.12 (m, 2H). MS (ESI) *m/z* 326 (M+H)⁺.

Cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-9-nitro-2,6-methano-3-benzazocine-8-carbonitrile (23)—Using a procedure similar to that used to prepare **22**, compound **21** was converted to **23** (quantitative yield) as an off-white foam. ¹H NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H), 7.75 (s, 1H), 3.22 (m, 1H), 3.08 (d, 1H, *J* = 19.8 Hz), 2.79 (m, 2H), 2.47 (m, 1H), 2.32 (m, 1H), 2.10-1.78 (m, 3H), 1.46 (s, 3H), 1.33 (m, 1H), 0.87 (m, 1H), 0.83 (d, 3H, *J* = 7.1 Hz), 0.54 (m, 2H), 0.12 (m, 2H).

Cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-7-nitro-2,6-methano-3-benzazocine-8-carboxamide (24)—A solution of **22** (0.11 g, 0.33 mmol) dissolved in t-BuOH (2.0 mL) was heated at 58 °C and KOH (0.056 g, 1.0 mmol) was added. After stirring at 58 °C for 1 h, brine and EtOAc were added. The organic phase was dried over Na₂SO₄, filtered, and concentrated to give a crude product which was purified by silica gel flash chromatography (CH₂Cl₂:CH₃OH:NH₄OH; 20:1:0.1) to give **24** as an off-white solid (0.098 g, 85%). Crystallization of this solid from acetone followed by a recrystallization from i-PrOH/t-BuOH gave crystals having mp 190 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.03 (s, 1H), 7.54 (s, 1H), 7.38 (s, 2H), 3.04 (m, 1H), 2.96 (d, 1H, *J* = 19.5 Hz), 2.76 (m, 2H), 2.38 (m, 1H), 2.24 (m, 1H), 2.06-1.56 (m, 3H), 1.19 (m, 4H), 0.79 (m, 1H), 0.73 (d, 3H, *J* = 6.8 Hz), 0.44 (m, 2H), 0.07 (m, 2H); MS (ESI) *m/z* 344 (M+H)⁺; Anal. Calcd. for C₁₉H₂₅N₃O₃·0.5 H₂O: C 64.75, H 7.44, N 11.92. Found: C 64.47, H 7.21, N 11.56.

Cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-9-nitro-2,6-methano-3-benzazocine-8-carboxamide (25)—Using a procedure similar to that used to prepare **24**, compound **23** was converted to **25** (45%) as an off-white foam. ¹H NMR (500 MHz, CDCl₃) δ 7.80 (s, 1H), 7.42 (s, 1H), 5.89 (m, 2H), 3.20 (m, 1H), 3.03 (d, 1H, *J* = 19.0 Hz), 2.75 (m, 2H), 2.47 (m, 1H), 2.33 (m, 1H), 2.06-1.82 (m, 3H), 1.43 (s, 3H), 1.34 (m, 1H), 0.87 (m, 1H), 0.83 (d, 3H, *J* = 7.1 Hz), 0.53 (m, 2H), 0.12 (m, 2H); MS (ESI) *m/z* 344 (M+H)⁺; Anal. Calcd. for C₁₉H₂₅N₃O₃·0.25 H₂O: C 65.59, H 7.39, N 12.08. Found: C 65.39, H 7.38, N 11.93.

Cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-7-amino-2,6-methano-3-benzazocine-8-carboxamide (26)—To a solution of **24** (0.15 g, 0.44 mmol) dissolved in MeOH (20 mL) was added 10% Pd/C (0.093 g). The resulting mixture was subjected to 55 psi H₂ in a Parr shaker for 3d at 25 °C. The mixture was filtered and concentrated to give a crude product that was purified by silica gel flash chromatography (CH₂Cl₂:CH₃OH:NH₄OH; 30:1:0.1) giving **26** (0.060 g, 44%) as a white foam. ¹H NMR (500 MHz, CDCl₃) δ 7.14 (d, 1H, *J* = 8.1 Hz), 6.42 (d, 1H, *J* = 8.1 Hz), 6.12 (s, 1H), 5.58 (br s, 2H), 3.09 (m, 1H), 2.76 (m, 3H), 2.24 (m, 1H), 2.28 (m, 1H), 2.06-1.70 (m, 3H), 1.59 (s, 3H), 1.58 (m, 1H), 0.91 (d, 3H, *J* = 7.1 Hz), 0.86 (m, 1H), 0.51 (m, 2H), 0.10 (m, 2H); MS (ESI) *m/z* 314 (M+H)⁺; Anal. Calcd. for C₁₉H₂₇N₃O·0.25 H₂O: C 71.78, H 8.72, N 13.22. Found: C 72.00, H 8.84, N 12.98.

Cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-9-amino-2,6-methano-3-benzazocine-8-carboxamide (27)—Using a procedure similar to that used to prepare **26**, compound **25** was converted to **27** (63%) as an off-white foam. ¹H NMR (500 MHz, CDCl₃) δ 7.20 (s, 1H), 6.42 (s, 1H), 5.61 (br s, 2H), 5.42 (s, 2H), 3.10 (m, 1H), 2.84 (d, 1H, *J* = 18.8 Hz), 2.75-2.53 (m, 2H), 2.46 (m, 1H), 2.30 (m, 1H), 2.06-1.80 (m, 3H), 1.35 (s, 3H), 1.27 (m, 1H), 0.87 (m, 1H), 0.84 (d, 3H, *J* = 7.1 Hz), 0.51 (m, 2H), 0.10 (m, 2H); MS (ESI) *m/z* 314 (M+H)⁺; Anal. Calcd. for C₁₉H₂₇N₃O·0.25 H₂O: C 71.78, H 8.72, N 13.22. Found: C 72.00, H 8.73, N 13.27.

7,8-Fused pyrimidinone derivative 11—A mixture of **26** (0.035 g, 0.11 mmol) and 2.0 mL of 88% formic acid was heated at 120 °C under microwave radiation for 30 min. The reaction mixture was basified using excess NH₄OH and the organic material was extracted into ethyl acetate. The organic phase was washed with brine, dried over Na₂SO₄ and concentrated giving a crude product that was purified by silica gel chromatography (Combiflash - CH₂Cl₂:CH₃OH:NH₄OH; 20:1:0.1) giving **11** (0.020 gm, 54%) as an off-white foam. Further crystallization from acetone gave white crystals (mp 220 °C): ¹H NMR (500 MHz, CDCl₃) δ 10.90 (br s, 1H), 8.08 (d, 1H, *J* = 8.1 Hz), 7.99 (s, 1H), 7.25 (d, 1H, *J* = 8.1 Hz), 3.19 (m, 1H), 2.93 (m, 2H), 2.77 (m, 1H), 2.48 (m, 1H), 2.29 (m, 1H), 2.06 (m, 1H), 1.90 (m, 2H), 1.81 (s,

3H), 1.64 (m, 1H), 0.90 (d, 3H, $J = 7.1$ Hz), 0.88 (m, 1H), 0.51 (m, 2H), 0.10 (m, 2H); MS (ESI) m/z 324 (M+H)⁺; Anal. Calcd. for C₂₀H₂₅N₃O: C 74.27, H 7.79, N 12.99. Found: C 73.95, H 7.86, N 12.78.

8,9-Fused pyrimidinone derivative 10—Using a procedure similar to that used to prepare **11**, compound **27** (0.021 g, 0.067 mmol) was converted to **10** (0.010 gm, 46%) as an off-white foam: ¹H NMR (500 MHz, CDCl₃) δ 11.10 (br s, 1H), 8.19 (s, 1H), 8.05 (s, 1H), 7.48 (s, 1H), 3.23 (m, 1H), 3.14 (d, 1H, $J = 19.3$ Hz), 2.91-2.72 (m, 2H), 2.51 (m, 1H), 2.35 (m, 1H), 2.08-1.86 (m, 3H), 1.52 (s, 3H), 1.38 (m, 1H), 0.90 (m, 1H), 0.87 (d, 3H, $J = 7.1$ Hz), 0.88 (m, 1H), 0.53 (m, 2H), 0.13 (m, 2H); MS (ESI) m/z 324 (M+H)⁺; Anal. Calcd. for C₂₀H₂₅N₃O·0.25 H₂O: C 73.25, H 7.84, N 12.81. Found: C 73.14, H 7.90, N 12.38.

Cis-(±)-7-Amino-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocine-8-carbonitrile (28)—A mixture of **26** (0.22 g, 0.70 mmol), POCl₃ (0.11 gm, 0.70 mmol), and pyridine (2.0 mL) was heated at 100 °C for 20 min under microwave radiation and concentrated. The residue was dissolved in 1.0 N HCl and stirred for 1 h at 25 °C. The reaction mixture was made basic with saturated NaHCO₃/crushed ice and the organic material was extracted into CH₂Cl₂. The organic layer were washed with brine, dried over Na₂SO₄, filtered and concentrated to give a crude product that was purified by silica gel chromatography (Combiflash - CH₂Cl₂:CH₃OH:NH₄OH) to give **28** as a brownish oil (0.11 g) in 54% yield: ¹H NMR (500 MHz, CDCl₃) δ 7.07 (d, 1H, $J = 8.5$ Hz), 6.41 (d, 1H, $J = 8.8$ Hz), 3.16 (m, 1H), 2.70 (m, 4H), 2.46 (m, 1H), 2.30 (m, 1H), 2.07-1.70 (m, 3H), 1.64 (m, 4H), 0.94 (d, 3H, $J = 6.8$ Hz), 0.88 (m, 1H), 0.53 (m, 2H), 0.12 (m, 2H).

Cis-(±)-9-Amino-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocine-8-carbonitrile (30)—A mixture of **23** (0.180 g, 0.55 mmol), 10% Pd/C and CH₃OH (20 mL) was subjected to 40 psi H₂ in a Parr shaker at 25 °C for 15 h. The mixture was filtered and concentrated to give **30** as a crude product that was purified by silica gel chromatography (Combiflash - CH₂Cl₂:CH₃OH:NH₄OH) to give a brownish solid (0.070 g, 47%): ¹H NMR (500 MHz, CDCl₃) δ 7.25 (s, 1H), 6.47 (s, 1H), 4.18 (s, 2H), 3.15 (m, 1H), 2.86 (d, 1H, $J = 19.0$ Hz), 2.80-2.58 (m, 2H), 2.48 (m, 1H), 2.33 (m, 1H), 1.94 (m, 3H), 1.32 (s, 3H), 1.25 (m, 1H), 0.90 (m, 1H), 0.81 (d, 3H, $J = 7.1$ Hz), 0.53 (m, 2H), 0.12 (m, 2H); MS (ESI) m/z 296 (M+H)⁺.

7,8-Fused aminopyrimidine derivative 12—A mixture of **28** (0.11 g, 0.38 mmol), CH(OCH₃)₃ (2 mL) and 4 Å molecular sieves was heated at 140 °C for 48 h. The reaction mixture was filtered and concentrated to give imidate intermediate **29** (0.120 g) which, without further purification, was combined with methanol saturated with ammonia gas. The resulting mixture was heated for 1 h at 100 °C under microwave radiation and then made basic with concentrated ammonia. After dilution with H₂O, the organic material was extracted into CH₂Cl₂ and the organic layer was washed with brine, dried over Na₂SO₄ and concentrated to give mixture that was purified by silica gel chromatography (Combiflash - CH₂Cl₂:CH₃OH:NH₄OH) and crystallization. The desired product **12** (0.074 gm) was obtained in 56% yield (2 steps) as an off-white solid: mp 190 °C: NMR (500 MHz, CDCl₃) δ 8.56 (s, 1H), 7.49 (d, 1H, $J = 8.3$ Hz), 7.20 (d, 1H, $J = 8.3$ Hz), 5.54 (s, 2H), 3.20 (m, 1H), 2.92 (m, 2H), 2.76 (m, 1H), 2.48 (m, 1H), 2.29 (m, 1H), 2.19 (m, 1H), 1.94 (m, 4H), 1.89 (s, 3H), 0.91 (d, 3H, $J = 7.1$ Hz), 0.89 (m, 1H), 0.51 (m, 2H), 0.10 (m, 2H); MS (ESI) m/z 323 (M+H)⁺; Anal. Calcd. for C₂₀H₂₆N₄·0.25 H₂O: C 73.47, H 8.17, N 17.14. Found: C 73.59, H 8.04, N 16.92.

8,9-Fused aminopyrimidine derivative 13—Using a procedure similar to that used to prepare **12**, compound **30** was converted to imidate intermediate **31** which was then converted to **13** (86%) as an off-white foam: ¹H NMR (500 MHz, CDCl₃) δ 8.56 (s, 1H), 7.62 (s, 1H),

7.58 (s, 1H), 6.00 (s, 2H), 3.23 (m, 1H), 3.18 (d, 1H, $J = 19.0$ Hz), 2.89 (m, 1H), 2.73 (m, 1H), 2.51 (m, 1H), 2.35 (m, 1H), 2.01 (m, 3H), 1.48 (s, 3H), 1.35 (m, 1H), 0.89 (m, 1H), 0.87 (d, 3H, $J = 7.3$ Hz), 0.53 (m, 2H), 0.13 (m, 2H); MS (ESI) m/z 323 (M+H)⁺; C₂₀H₂₆N₄·0.25 H₂O: C 73.47, H 8.17, N 17.14. Found: C 73.33, H 8.03, N 16.85.

7,8-Fused biphenylethylaminopyrimidine derivative 14—Using a procedure similar to that used to prepare **12** (except acetic acid was added), compound **29** was treated with 4-biphenylethylamine to provide to **14** (71%) as an off-white foam: NMR (500 MHz, CDCl₃) δ 8.64 (s, 1H), 7.58 (m, 4H), 7.45 (m, 2H), 7.34 (m, 3H), 7.29 (d, 1H, $J = 8.5$ Hz), 7.13 (d, 1H, $J = 8.5$ Hz), 5.56 (m, 1H), 3.93 (m, 2H), 3.19 (m, 1H), 3.06 (t, 2H, $J = 6.6$ Hz), 2.89 (m, 2H), 2.77 (m, 1H), 2.47 (m, 1H), 2.28 (m, 1H), 2.21 (m, 1H), 1.90 (s, 3H), 1.87 (m, 1H); 1.63 (m, 2H), 0.90 (d, 3H, $J = 7.1$ Hz), 0.88 (m, 1H), 0.51 (m, 2H), 0.10 (m, 2H); MS (ESI) m/z 503 (M+H)⁺; Anal. Calcd. for C₃₄H₃₈N₄·0.5 H₂O: C 79.81, H 7.68, N 10.95. Found: C 79.88, H 7.66, N 10.83.

7,8-Fused benzylaminopyrimidine derivative 15—Using a procedure similar to that used to prepare **12**, compound **29** was treated with benzylamine to provide **15** (69%) as an off-white foam: NMR (500 MHz, CDCl₃) δ 8.64 (s, 1H), 7.44 (d, 1H, $J = 8.5$ Hz), 7.40–7.30 (m, 5H); 7.15 (d, 1H, $J = 8.3$ Hz), 5.81 (m, 1H), 4.83 (d, 2H, $J = 5.4$ Hz), 3.20 (m, 1H), 2.91 (m, 2H), 2.77 (m, 1H), 2.48 (m, 1H), 2.29 (m, 1H), 2.22 (m, 1H), 1.93 (m, 2H), 1.90 (s, 3H), 1.88 (m, 1H); 0.90 (d, 3H, $J = 7.1$ Hz), 0.88 (m, 1H), 0.51 (m, 2H), 0.10 (m, 2H); MS (ESI) m/z 413 (M+H)⁺; Anal. Calcd. for C₂₇H₃₂N₄·0.5 H₂O: C 76.92, H 7.89, N 13.29. Found: C 76.77, H 7.99, N 12.90.

8,9-Fused biphenylethylaminopyrimidine derivative 16—A mixture of **27** (0.084 g, 0.27 mmol), POCl₃ (0.41 g, 2.7 mmol), and DMF (3.0 mL) was heated at 100 °C under microwave radiation for 10 min and concentrated. The resulting dark oil was dissolved in H₂O, made basic with Na₂CO₃ and extracted (X3) with CH₂Cl₂. The combined organic extracts were dried over Na₂SO₄ and concentrated to give mixture that was purified by silica gel chromatography (CH₂Cl₂:CH₃OH:NH₄OH) giving the desired amidine intermediate **32** in 89% yield. Compound **32** (0.15 g, 0.43 mmol) was treated with 4-biphenylethylamine (0.10 g, 0.51 mmol) and 30% HOAc in CH₃CN (3.0 mL) at 160 °C under microwave radiation for 5 min. The reaction mixture was cooled down and partitioned between saturated Na₂CO₃ and CH₂Cl₂. The organic phase was washed with brine, dried over Na₂SO₄ and concentrated to give a crude product that was purified by silica gel chromatography (Combiflash – Hexane:EtOAc:Et₃N 80:20:0.5 to 50:50:0.5) to provide to **16** (0.18 g, 86%) as an off-white foam: NMR (500 MHz, CDCl₃) δ 8.63 (s, 1H), 7.58 (m, 4H), 7.54 (s, 1H), 7.45 (m, 2H), 7.36 (m, 4H), 5.72 (m, 1H), 3.96 (m, 2H), 3.20 (m, 1H), 3.16 (d, 1H, $J = 19.1$ Hz), 3.09 (t, 2H, $J = 7.1$ Hz), 2.80 (m, 1H), 2.71 (m, 1H), 2.50 (m, 1H), 2.34 (m, 1H), 2.04–1.94 (m, 3H), 1.43 (s, 3H), 1.30 (m, 1H), 0.88 (m, 1H), 0.85 (d, 3H, $J = 7.1$ Hz), 0.52 (m, 2H), 0.12 (m, 2H); MS (ESI) m/z 503 (M+H)⁺; Anal. Calcd. for C₃₄H₃₈N₄·0.5 H₂O: C 79.81, H 7.68, N 10.95. Found: C 79.52, H 7.64, N 10.83.

8,9-Fused benzylaminopyrimidine derivative 17—Using a procedure similar to that used to prepare **16**, compound **32** was treated with benzylamine to provide to **17** (92 %) as an off-white solid: NMR (500 MHz, CDCl₃) δ 8.64 (s, 1H), 7.56 (m, 1H), 7.50 (s, 1H), 7.44 (d, 2H, $J = 7.3$ Hz), 7.39 (t, 2H, $J = 7.3$ Hz), 7.34 (d, 1H, $J = 7.3$ Hz), 5.94 (br s, 1H), 4.90 (m, 2H), 3.22 (m, 1H), 3.17 (d, 1H, $J = 19.0$ Hz), 2.88 (m, 1H), 2.72 (m, 1H), 2.51 (m, 1H), 2.34 (m, 1H), 1.99 (m, 3H), 1.47 (s, 3H), 1.33 (m, 1H), 0.88 (m, 1H), 0.86 (d, 3H, $J = 7.1$ Hz), 0.52 (m, 2H), 0.12 (m, 2H); MS (ESI) m/z 413 (M+H)⁺; C₂₇H₃₂N₄·H₂O: C 75.31, H 7.96, N 13.01. Found: C 75.64, H 7.73, N 13.02.

Cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-*N*-methoxy-6,11-dimethyl-2,6-methano-3-benzazocine-8-carboxamide (34)—A solution of **33**⁸ (240 mg, 0.606 mmol) and methoxylamine hydrochloride (61 mg, 0.727 mmol) in 3 mL of dry pyridine was stirred at room temperature for 12 h. The solvent was removed in vacuo and the residue was taken up in methylene chloride (40 mL), and washed with saturated sodium bicarbonate solution, water, and brine. The organic phase was dried over sodium sulfate, filtered, and concentrated to give a brown residue, which was purified by flash chromatography (CH₂Cl₂:CH₃OH:NH₄OH 20:1:0.1) to give **34** as an off-white foam (159 mg, 0.485 mmol, 80%): ¹H NMR (500 MHz, CDCl₃) δ 8.64 (bs, 1H), 7.64 (d, 1H, *J* = 1.5 Hz), 7.42 (dd, 1H, 7.8, 2.5 Hz), 7.12 (d, 1H, *J* = 7.8 Hz), 3.89 (s, 3H), 3.15 (m, 1H), 2.96 (d, 1H, *J* = 18.6 Hz), 2.70 (m, 2H), 2.46 (m, 1H), 2.32 (m, 1H), 1.91 (m, 3H), 1.42 (s, 3H), 1.33 (m, 1H), 0.86 (m, 1H), 0.82 (d, 3H, *J* = 7.2 Hz), 0.51 (m, 2H), 0.11 (m, 2H); MS (ESI) *m/z* 329 (M+H)⁺; IR (CH₂Cl₂) *v*_{max} 3464, 3196, 1643 cm⁻¹; Anal. Calcd. for C₂₀H₂₈N₂O₂·0.25H₂O: C 72.15, H 8.63, N 8.41. Found: C 72.15, H 8.67, N 8.13.

Cis-(±)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-*N*-methoxy-6,9,11-trimethyl-2,6-methano-3-benzazocine-8-carboxamide (35)—Conditions of Fisher and coworkers were used.⁹ *sec*-Butyllithium (1.4 M in cyclohexane, 4.6 mL, 4.57 mmol) was added to a mixture of **34** (100 mg, 0.305 mmol) and TMEDA (530 mg, 4.57 mmol) in dry THF at -78 °C under nitrogen atmosphere. The resulting mixture was warmed to -20 °C, stirred for 10 min and cooled to -78 °C again. Iodomethane (649 mg, 4.57 mmol) was added dropwise and the resulting mixture was stirred for 5 min. The reaction was quenched with 20 mL of saturated ammonia chloride and extracted with EtOAc (3×20 mL). The combined organic phases were washed twice with water and once with brine, dried over sodium sulfate, filtered, and concentrated to give **35** as a brown oil (146 mg, estimated yield 74%). There was small amount of starting material in this oil and it is difficult to separate starting material from product using flash chromatography because these two compounds have the same R_f value on silica gel TLC plate. Therefore, **35** was used in next step without further purification. ¹H NMR (500 MHz, CDCl₃) δ 7.19 (s, 1H), 6.90 (s, 1H), 3.86 (s, 3H), 3.12 (m, 1H), 2.87 (d, 1H, *J* = 19 Hz), 2.64 (m, 2H), 2.42 (m, 1H), 2.36 (s, 3H), 2.28 (m, 1H), 1.86 (m, 3H), 1.34 (s, 3H), 1.26 (m, 1H), 0.85 (m, 1H), 0.85 (d, 3H, *J* = 6.8 Hz), 0.50 (m, 2H), 0.10 (m, 2H); MS (ESI) *m/z* 343 (M+H)⁺.

8,9-Fused *N*-methoxypyridinone derivative 36—Conditions of Fisher and coworkers were used.⁹ *sec*-Butyllithium (1.4 M in cyclohexane, 2.3 mL, 2.99 mmol) was added dropwise to a solution of **35** (146 mg, 0.427 mmol) in 2 mL of dry THF under argon at -78 °C. The resulting mixture was stirred for 5 min. DMF (0.23 mL) was added and the reaction mixture was stirred for additional 5 min. Then the reaction was quenched with 20 mL of saturated ammonia chloride and extracted with EtOAc (3×20 mL). The combined organic phases were washed twice with water and once with brine, dried over sodium sulfate, filtered, and concentrated to give a brown oil, which was mixed with 1 mL of concentrated HCl and stirred for 1 h. The reaction mixture was then made basic using 5 N NaOH solution and extracted with EtOAc (3×20 mL). The combined organic phases were washed twice with water and once with brine, dried over sodium sulfate, filtered, and concentrated to give a brown oil, which was purified by flash chromatography (CH₂Cl₂:CH₃OH:NH₄OH 25:1:0.1) to give **36** as a white foam (0.054 g, 0.153 mmol) in 50% overall from **34**: ¹H NMR (500 MHz, CDCl₃) δ 8.34 (s, 1H), 7.25 (d, 1H, *J* = 8.0 Hz), 7.24 (s, 1H), 6.37 (d, 1H, *J* = 8.0 Hz), 4.08 (s, 3H), 3.19 (m, 1H), 3.08 (d, 1H, *J* = 19 Hz), 2.81 (m, 1H), 2.71 (m, 1H), 2.49 (m, 1H), 2.32 (m, 1H), 1.97 (m, 3H), 1.52 (s, 3H), 1.39 (m, 1H), 0.88 (m, 1H), 0.84 (d, 3H, *J* = 7.0 Hz), 0.52 (m, 2H), 0.11 (m, 2H); MS (ESI) *m/z* 353 (M+H)⁺.

8,9-Fused pyridinone derivative 37—Conditions of Fisher and coworkers were used.⁹ A solution of titanium(III) chloride (0.197 g, 1.28 mmol) in 2.5 mL of 6 N HCl was added to a solution of **36** (45 mg, 0.128 mmol) in 1 mL of EtOH. The resulting mixture was irradiated with microwaves at 100 °C for 30 min. The cooled reaction mixture was poured onto a mixture of ice and water and basified with 5 N NaOH to approximately pH 13. Air was bubbled through the solution until the blue color disappeared. White precipitants were observed in solution. The mixture was extracted with EtOAc (3×20 mL). The combined organic phases were washed twice with water and once with brine, dried over sodium sulfate, filtered, and concentrated to give a brown residue, which was purified by flash chromatography (CH₂Cl₂:CH₃OH:NH₄OH 25:1:0.1) to give **37** as a white foam (0.026 g, 0.0819 mmol, 64%): ¹H NMR (500 MHz, CDCl₃) δ 11.89 (bs, 1H), 8.33 (s, 1H), 7.29 (s, 1H), 7.15 (d, 1H, *J* = 7.0 Hz), 6.49 (d, 1H, *J* = 7.0 Hz), 3.22 (m, 1H), 3.11 (d, 1H, *J* = 18.5 Hz), 2.84 (m, 1H), 2.74 (m, 1H), 2.51 (m, 1H), 2.35 (m, 1H), 2.00 (m, 3H), 1.54 (s, 3H), 1.41 (m, 1H), 0.89 (m, 1H), 0.87 (d, 3H, *J* = 7.0 Hz), 0.52 (m, 2H), 0.11 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 164.81, 143.04, 142.86, 135.93, 127.41, 124.74, 124.48, 124.22, 106.29, 60.11, 57.05, 45.91, 42.72, 41.86, 37.12, 26.01, 24.43, 14.44, 9.58, 4.22, 3.82; MS (ESI) *m/z* 323 (M+H)⁺; Anal. Calcd. for C₂₁H₂₆N₂O·0.5H₂O: C 76.10, H 8.21, N 8.45. Found: C 76.20, H 8.36, N 8.01.

5.2. Opioid Receptor Binding Assays

Binding assays used to screen compounds are similar to those previously reported.¹⁵ Membrane protein from CHO cells that stably expressed one type of the human opioid receptor were incubated with 12 different concentrations of the compound in the presence of either 1 nM [³H]U69,593 (μ), 0.25 nM [³H]DAMGO (δ) or 0.2 nM [³H]naltrindole (κ) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25°C. Incubation times of 60 min were used for [³H]U69,593 and [³H]DAMGO. Because of a slower association of [³H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [³H]naltrindole also contained 10 mM MgCl₂ and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 μM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber filters using a Brandel 48-well cell harvester. The filters were subsequently washed three times with 3 mL of cold 50 mM Tris-HCl, pH 7.5, and were counted in 2 mL Ecoscint A scintillation fluid. For [³H]naltrindole and [³H]U69,593 binding, the filters were soaked in 0.1% polyethylenimine for at least 60 min before use. IC₅₀ values will be calculated by least squares fit to a logarithm-probit analysis. *K_i* values of unlabeled compounds were calculated from the equation *K_i* = (IC₅₀)/1+S where S = (concentration of radioligand)/(*K_d* of radioligand)¹⁶ The *K_d* values for [³H]DAMGO, [³H]U69,593, and [³H]naltrindole were 0.56 nM, 0.34 nM, and 0.10 nM, respectively. Data are the mean ± SEM from at least three experiments performed in triplicate.

5.3. [³⁵S]GTPγS Binding Assays

Procedure similar to those previously reported was used.¹² In a final volume of 0.5 mL, 12 different concentrations of each test compound were incubated with 15 μg (κ) or 7.5 μg (μ) of CHO cell membranes that stably expressed either the human κ, δ or μ opioid receptor. The assay buffer consisted of 50 mM Tris-HCl, pH 7.4, 3 mM MgCl₂, 0.2 mM EGTA, 3 μM GDP, and 100 mM NaCl. The final concentration of [³⁵S]GTPγS was 0.080 nM. Nonspecific binding was measured by inclusion of 10 μM GTPγS. Binding was initiated by the addition of the membranes. After an incubation of 60 min at 30°C, the samples were filtered through Schleicher & Schuell No. 32 glass fiber filters. The filters were washed three times with cold 50 mM Tris-HCl, pH 7.5, and were counted in 2 mL of Ecoscint scintillation fluid. Data are the mean E_{max} and EC₅₀ values ± S.E.M. from at least three separate experiments, performed in triplicate. For calculation of the E_{max} values, the basal [³⁵S]GTPγS binding was set at 0%. To determine antagonist activity of a compound at the μ opioid receptors, CHO membranes expressing the μ opioid receptor, were incubated with 12 different concentrations of the

compound in the presence of 200 nM of the μ agonist DAMGO. To determine antagonist activity of a compound at the κ opioid receptors, CHO membranes expressing the κ opioid receptor, were incubated with the compound in the presence of 100 nM of the κ agonist U50,488.

Acknowledgements

We gratefully acknowledge the contributions of Rensselaer's mass spectroscopist Dr. Dmitri Zagorevski and the technical assistance provided by Brian I. Knapp of the University of Rochester. Funding of this research was from NIDA (DA12180 and KO5-DA00360) and the NSF (Agilent 1100 series LC/MSD system).

References and Notes

1. Wentland MP, Lou R, Ye Y, Cohen DJ, Richardson GP, Bidlack JM. *Bioorg Med Chem Lett* 2001;11:623. [PubMed: 11266156]
2. Archer S, Glick SD, Bidlack JM. *Neurochem Res* 1996;21:1369–1373. [PubMed: 8947927]
3. Zhang A, Xiong W, Bidlack JM, Hilbert JE, Knapp BI, Wentland MP, Neumeyer JL. *J Med Chem* 2004;47:165. [PubMed: 14695830]
4. Wentland MP, Lou R, Dehnhardt CM, Duan W, Cohen DJ, Bidlack JM. *Bioorg Med Chem Lett* 2001;11:1717. [PubMed: 11425545]
5. Wentland MP, Lu Q, Lou R, Knapp BI, Bidlack JM. *Bioorg Med Chem Lett* 2005;15:2107. [PubMed: 15808478]
6. Wentland MP, Sun X, Bu Y, Lou R, Cohen DJ, Bidlack JM. *Bioorg Med Chem Lett* 2005;15:2547. [PubMed: 15863314]
7. (a) Bachmann WE, Brockway CE. *J Org Chem* 1948;13:384. (b) Zhang Q, Chen Y, Zheng Y, Xia P, Xia Y, Yang Z, Bastow KF, Morris-Natschke SL, Lee K-H. *Bioorg Med Chem* 2003;11:1031. [PubMed: 12614889]
8. Lou R, VanAlstine M, Sun X, Wentland MP. *Tet Lett* 2003;44:2477.
9. Fisher LE, Caroon JM, Jahangir S, Stabler R, Lundberg S, Muchowski JM. *J Org Chem* 1993;58:3643.
10. Peng X, Knapp BI, Bidlack JM, Neumeyer JL. *Bioorg Med Chem* 2007;15:4106. [PubMed: 17433695]
11. Ganorkar, RR.; Lu, Q.; Wentland, MP.; Bidlack, JM. Abstracts of Papers, 234th ACS National Meeting; Boston, MA, United States. August 19-23, 2007; MEDI-140
12. Wentland MP, VanAlstine M, Kucejko R, Lou R, Cohen DJ, Parkhill AL, Bidlack JM. *J Med Chem* 2006;49:5635. [PubMed: 16942039]
13. VanAlstine MA, Wentland MP, Cohen DJ, Bidlack JM. *Bioorg Med Chem Lett* 2007;17:6516. [PubMed: 17935988]
14. Abraham MH, Platts JA. *J Org Chem* 2001;66:3484. [PubMed: 11348133]
15. Neumeyer JL, Zhang A, Xiong W, Gu X, Hilbert JE, Knapp BI, Negus SS, Mello NK, Bidlack JM. *J Med Chem* 2003;46:5162. [PubMed: 14613319]
16. Cheng YC, Prusoff WH. *Biochem Pharmacol* 1973;22:3099. [PubMed: 4202581]

Scheme 1. Reagents and conditions

(a) 69% HNO₃, CH₃CO₂H, 25 °C; (b) PhN(Tf)₂, Et₃N, CH₂Cl₂, 25 °C; (c) Zn(CN)₂, Pd (PPh₃)₄, microwaves, 150 °C; (d) t-BuOH, KOH, 82 °C; (e) MeOH, 10% Pd/C, H₂, 25 °C; (f) 88% HCO₂H; microwaves, 120 °C.

Scheme 2. Reagents and conditions

(a) POCl₃, pyridine, microwaves, 100 °C; (b) CH(OCH₃)₃, 4Å molecular sieves, 140 °C; (c) CH₃OH, NH₃, HOAc, microwaves, 100°C; (d) CH₃OH, H₂NCH₂CH₂-4-(C₆H₄)C₆H₅, HOAc, microwaves, 160°C; (e) CH₃OH, PhCH₂NH₂, HOAc, microwaves, 160°C.

Scheme 3. Reagents and conditions

(a) 10% Pd/C, CH₃OH, H₂, 25 °C; (b) CH(OCH₃)₃, 4 Å molecular sieves, 140 °C; (c) CH₃OH, NH₃, microwaves, 120 °C.

Scheme 4. Reagents and conditions

(a) POCl₃, DMF, microwaves radiation, 100 °C; (b) CH₃CO₂H, H₂NCH₂CH₂-4-(C₆H₄)C₆H₅, CH₃CN, microwaves, 160°C; (c) CH₃CO₂H, PhCH₂NH₂, CH₃CN, microwaves, 160°C.

Scheme 5. Reagents and conditions

(a) CH₃ONH₂·HCl, pyr; (b) sec-BuLi, TMEDA, THF, -78 °C; (c) MeI; (d) sec-BuLi, THF, -78 °C; (e) DMF; (f) TiCl₃, HCl, EtOH, 100 °C, microwaves.

Table 1

Opioid receptor binding data for 7,8- and 8,9-ring fused 2,6-methano-3-benzazocines and related compounds.

compd	[³ H]DAMGO (μ)	K _i (nM ± S.E.) ^a [³ H]Naltrindole (δ)	[³ H]U69,593 (κ)
1 (8-CAC) ^b	0.31 ± 0.03	5.2 ± 0.36	0.06 ± 0.001
10 ^c	170 ± 6.7	780 ± 32	12 ± 0.65
11 ^c	270 ± 33	2000 ± 49	160 ± 7.1
12 ^c	0.55 ± 0.018	120 ± 8.5	1.0 ± 0.071
13 ^c	890 ± 39	>10 μM	560 ± 23
14 ^c	6.9 ± 0.33	52 ± 2.6	8.6 ± 1.5
15 ^c	44 ± 0.76	1500 ± 68	240 ± 1.8
16 ^c	28 ± 1.9	410 ± 61	140 ± 4.4
17 ^c	88 ± 7.2	1000 ± 37	48 ± 2.3
18 ^c	32 ± 2.6	1900 ± 204	3.2 ± 0.14
19 ^c	3800 ± 166	>10 μM	580 ± 5.4
24 ^c	20 ± 1.2	220 ± 20	34 ± 1.2
25 ^c	630 ± 41	730 ± 21	110 ± 11
26 ^c	0.55 ± 0.029	35 ± 0.036	0.70 ± 0.036
27 ^c	88 ± 5.2	2000 ± 12	32 ± 1.7
37 ^c	5.5 ± 0.67	74 ± 6.8	0.74 ± 0.10
38 ^d	0.30 ± 0.036	0.74 ± 0.019	1.8 ± 0.19
39 ^d	27 ± 5.5	210 ± 55	36 ± 1.1

^a See experimental section.^b See reference 13.^c Proton NMR, IR and MS were consistent with the assigned structures of all new compounds. C, H, and N elemental analyses were obtained for all new targets and most intermediates and were within ±0.4% of theoretical values.^d See reference 12.

Table 2

EC₅₀ and E_{max} values for the stimulation of [³⁵S]GTPγS binding and IC₅₀ and I_{max} values for the inhibition of agonist-stimulated [³⁵S]GTPγS binding to the human μ and κ opioid receptors.^a

Compound	EC ₅₀ (nM)	E _{max} (% maximal stimulation)	IC ₅₀ (nM)	I _{max} (% maximal inhibition)
Mu Opioid Receptor				
DAMGO	55 ± 7	116 ± 4	NI ^b	NI
12	NA	0.64 ± 1.0	28 ± 1.1	88 ± 3.1
26	NA	4.6 ± 1.7	31 ± 6.5	93 ± 1.5
37	NA	27 ± 3.5	850 ± 270	69 ± 6.7
Kappa Opioid Receptor				
U50,488	36 ± 5.0	77 ± 11	NI	NI
12	NA	6.3 ± 0.6	1300 ± 290	75 ± 4.7
26	15 ± 6.9	38 ± 3.0	NI	NI
37	60 ± 9.3	91 ± 9.8	NI	NI

^a See experimental section. Data are the mean values ± S.E.M. from at least three separate experiments, performed in triplicate. For calculation of the E_{max} values, the basal [³⁵S]GTPγS binding was set at 0%. For inhibition studies, 200 nM DAMGO was used as the agonist for the μ receptor and U50,488 at final concentration of 100 nM was used for the κ receptor.

^b NI → No Inhibition.

^c NA → Not applicable.